Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q1 2025 Earnings Call Transcript May 5, 2025Vertex Pharmaceuticals Incorporated misses on earnings expectations.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 37,947 | $18,397,627 | +2% | 0.47% |
| 2. | ARK Investment Management Catherine D. Wood | 26,344 | $12,772,279 | +4% | 0.13% |
| 3. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 22,808 | $11,057,775 | +3% | 4.88% |
| 4. | Leucadia National Ian Cumming And Joseph Steinberg | 19,484 | $9,446,233 | +40% | 0.08% |
| 5. | Impax Asset Management Ian Simm | 6,999 | $3,393,255 | +2% | 0.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $196.34 | 4,243 | Officer, Director | 73,754 | 2021-08-19 | Filing | |
| $195.14 | 5,757 | Officer, Director | 69,511 | 2021-08-19 | Filing | |
| $197.91 | 15,000 | Director | 41,210 | 2021-08-02 | Filing | |
| $218.79 | 3,905 | Director | 26,210 | 2020-11-10 | Filing | |
| $217.49 | 4,270 | Director | 22,305 | 2020-11-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $505.86 | 400 | Director | 4,831 | 2025-05-02 | Filing | |
| $510.00 | 3,231 | Officer | 23,281 | 2025-03-13 | Filing | |
| $500.00 | 3,298 | Officer | 51,671 | 2025-03-10 | Filing | |
| $499.99 | 3,242 | Officer | 51,239 | 2025-03-10 | Filing | |
| $500.00 | 3,231 | Officer | 26,512 | 2025-03-10 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,782,933 | $10,560,801,400 | 0.22% | |
| 2. | 5,062,442 | $2,454,373,096 | 1.72% | |
| 3. | 2,024,908 | $981,715,897 | 0.33% | |
| 4. | 1,711,665 | $829,849,218 | 0.16% | |
| 5. | 1,098,940 | $541,436,749 | 1.39% |
News See All
21 Stocks on Jim Cramer's Radar
“When you get a strong employment report like we did this morning, it does a lot of things that you need to know about. First, it takes a near-term recession kind of off the table.
Vertex Pharmaceuticals (VRTX) Surged on Increased Demand for its Cystic Fibrosis (CF) Franchise
GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Best Long Term Growth Stocks to Buy According to Billionaires
As per Barclays, the US administration announced numerous executive orders with reforms associated with world trade, immigration, and global geopolitics, resulting in elevated levels of uncertainty and...
Jim Cramer Nailed These 11 Stock Picks
On Thursday, April 3rd, the host of Mad Money opened the most recent show by addressing the growing concerns surrounding the current tariff policies.
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
Jim Cramer Looked At These 23 Stocks Recently
Jim Cramer, the host of Mad Money, offered an optimistic perspective on the market on Thursday as he challenged the prevailing pessimism among some on Wall Street.
Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer reiterated that the Trump administration has to clarify its narrative about tariffs to convince the average American about their utility...
13 High Growth Large Cap Stocks To Invest In
After two years of 25%+ gains, some investors worry that stocks are overvalued. Historically, the third year of a bull market is not usually spectacular, but it is not typically negative either.
15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Billionaire Hedge Funds
